Marina Biotech Announces Name Change to Adhera Therapeutics to More Closely Reflect the Mission of Improving Patient Outcomes

Research Triangle Park, NC, October 9, 2018 — Marina Biotech, Inc. (OTCQB: MRNA)), a commercial stage pharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis and pain, today announced that it has changed its name to Adhera Therapeutics, Inc. and that it will begin using the ticker ATRX, in each Read More

Marina Biotech Appoints Nancy R. Phelan to the Board of Directors

Research Triangle Park, NC – October 3, 2018 – Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis and pain, today announced that Nancy R. Phelan has been appointed to serve as a member of its Board of Directors, effective today. Ms. Read More

Marina Biotech Appoints Eric Teague as Chief Financial Officer

Research Triangle Park, NC – September 24, 2018 – Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, today announced the appointment of Eric Teague as Chief Financial Officer of the Company. “Marina is launching PRESTALIA and actively exploring Read More

Marina Biotech Appoints Jay D. Schwartz to serve as Senior Vice President, Commercial Operations

City of Industry, CA – Aug. 06, 2018 – Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, today announced that the company has appointed Jay D. Schwartz to serve as Senior Vice President, Commercial Operations. Mr. Schwartz is Read More

Marina Biotech Announces a New Publication on Prestalia®

City of Industry, CA – February 27, 2018 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today further progress with its FDA-Approved Prestalia® hypertension drug, with the issuance of a new and independent publication on Prestalia®:  Elliott WJ Read More

Marina Biotech Announces Agreement for Drug Development and Licensing with Autotelic Bio

City of Industry, CA – January 16, 2018 – Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today that the Company has entered into a binding agreement with Autotelic Bio Inc., to enter into a license of Marina’s IT-103 Read More

Scroll Up